Journal
INTERNAL MEDICINE
Volume 61, Issue 20, Pages 3101-3106Publisher
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.0104-22
Keywords
mRNA vaccine; sarcoidosis; COVID-19; uveitis; angiotensin-converting enzyme (ACE)
Categories
Funding
- Ministry of Education, Sciences, Sports, and Technology (MEXT) , Japan
- [21K 16106]
Ask authors/readers for more resources
This article reports a case of novel sarcoidosis development after BNT162b2 vaccination and reviews other similar reactions reported.
BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleosidemodified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensinconverting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available